Dajia Weikang: Announcement on completing the registration of industrial and commercial changes and issuing a business license
Dajia Weikang: Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders
Dajia Weikang: Legal Opinion of Hunan Qiyuan Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Dajia Weikang: Announcement on the change of business scope and completion of industrial and commercial registration of a wholly-owned subsidiary
Dajia Weikang: Announcement on the calculation of credit impairment preparations for the third quarter of 2024
Dajia Weikang: Notice on changing the company\'s registered capital, revising the “Articles of Association”, and registering industrial and commercial changes
Dajia Weikang: Notice on Convening the Fourth Extraordinary General Meeting of Shareholders in 2024
Dajia Weikang: Announcement on repurchasing shares to cancel and reduce registered capital and notify creditors
Dajia Weikang: Announcement on Establishing a Wholly-owned Subsidiary and Obtaining a Business License
Dajia Weikang: Summary table of non-operating capital expenditure and other related capital transactions for the first half year of 2024
Dajia Weikang: Announcement on the 2024 Semi-Annual Credit Impairment Preparation and Asset Impairment Preparation
Hunan Dajiaweikang Pharmaceutical Industry: Announcement regarding specific period of not reducing shareholding of company's stocks by subscribers.
Hunan Dajiaweikang Pharmaceutical Industry: Announcement on changing the continuously supervised sponsoring representative.
Hunan Dajiaweikang Pharmaceutical Industry: Announcement Regarding Change of Business Scope of Wholly-Owned Subsidiary and Completion of Industrial and Commercial Change Registration.
Hunan Dajiaweikang Pharmaceutical Industry: Announcement Regarding Change of Business Scope of Wholly-Owned Subsidiary and Completion of Industrial and Commercial Change Registration.
Hunan Dajiaweikang Pharmaceutical Industry: Legal Opinion of Hunan Qiyuan Law Firm on the 2023 Annual General Meeting of Shareholders of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Hunan Dajiaweikang Pharmaceutical Industry: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Dajia Weikang: Summary table on the use of non-operating capital and other related capital transactions in 2023
Dajia Weikang: Notice on Convening the 2023 Annual General Meeting of Shareholders
Dajia Weikang: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
No Data